Allison Hayes
Psychiatric/Mental Health · Danbury, CTNPI 1154879674
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 31.1% of the total. Reporting peaked in 2021 at $2,861 and has fallen 82.9% since, to $490 in 2025. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$468
- Lundbeck LLC$253
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$248
- Otsuka America Pharmaceutical, Inc.$232
- Teva Pharmaceuticals USA, Inc.$194
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,984100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $468 |
| Lundbeck LLC | 12 | $253 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $248 |
| Otsuka America Pharmaceutical, Inc. | 13 | $232 |
| Teva Pharmaceuticals USA, Inc. | 10 | $194 |
| Sunovion Pharmaceuticals Inc. | 10 | $170 |
| Jazz Pharmaceuticals Inc. | 8 | $153 |
| Neurocrine Biosciences, Inc. | 7 | $143 |
| Supernus Pharmaceuticals, Inc. | 7 | $126 |
| Adlon Therapeutics L.p. | 6 | $119 |
| Avanir Pharmaceuticals, Inc. | 6 | $114 |
| Vanda Pharmaceuticals Inc. | 5 | $83 |
| Corium, LLC | 5 | $77 |
| Indivior Inc. | 4 | $75 |
| Harmony Biosciences LLC | 2 | $70 |
| Tris Pharma Inc | 3 | $61 |
| Bausch Health US, LLC | 2 | $34 |
| Alkermes, Inc. | 2 | $33 |
| Hologic Sales And Service, LLC | 1 | $30 |
| Eisai Inc. | 2 | $26 |
| Merck | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $14 |
How this compares
$3,984 in reported general payments places this provider in the 90th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 27 | $35,403 |
| Trazodone Hcl | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Danbury
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Margaret ScaliaDanbury$8K
- Gregory GuionDanbury$6K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.